Image de couverture de livre

Characteristics of Patients with Myasthenia Gravis in the French Rare Disease Registry

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Jean‐Philippe Camdessanche, Andoni Echaniz‐Laguna, Guilhem Solé, Cécile Blein, Mariana Ciumas, Claude Messiaen, Anne‐Sophie Jannot, Shahram Attarian
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	European Journal of Neurology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database
par: Guilhem Solé, et autres
Publié: (2026)

Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database
par: Shahram Attarian, et autres
Publié: (2024)

Diagnostic Impasse and Wandering in Patients With Rare Neuromuscular Diseases: Insights Into Patient Characteristics From the French National Network for Rare Neuromuscular Diseases (FILNEMUS) and the French National Rare Disease Database (BNDMR)
par: Rémy Dumas, et autres
Publié: (2025)

Phenotype–genotype correlation in X‐linked Charcot‐Marie‐Tooth disease: A French cohort study
par: Luce Barbat du Closel, et autres
Publié: (2024)

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
par: Ali A. Habib, et autres
Publié: (2025)

MuSK‐Myasthenia Gravis and Cancer
par: Shigeaki Suzuki, et autres
Publié: (2024)

Reply to “MuSK‐Myasthenia Gravis and Cancer”
par: Silvia Falso, et autres
Publié: (2024)

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability
par: Maike Stein, et autres
Publié: (2025)

Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
par: Silvia Falso, et autres
Publié: (2024)

Causes of Death and Comorbidities in Adult Patients With Late‐Onset Pompe Disease: A French Pompe Registry Retrospective Study
par: Diana Maria Chitimus, et autres
Publié: (2025)

Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case–Control Study
par: Josefine Jul Jarbæk Nielsen, et autres
Publié: (2026)

Beyond the Surface: Investigating the Potential Mechanisms of Non‐Motor Symptoms in Myasthenia Gravis
par: Benqiao Wang, et autres
Publié: (2025)

Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures
par: Maike Stein, et autres
Publié: (2025)

Coexistence of Acute Demyelinating Polyneuropathy and LRP4‐Positive Myasthenia Gravis
par: Halit Fidancı, et autres
Publié: (2025)

Effects of Thymectomy in Late‐Onset Myasthenia Gravis: A Multi‐Center Longitudinal Retrospective Study
par: Jiaxin Chen, et autres
Publié: (2025)

Differences Between Females and Males in the Diagnostic Delay and Clinical Course of Thymectomised Myasthenia Gravis
par: Chris Myllynen, et autres
Publié: (2025)

A Distinct Immunological Signature in Late‐Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study
par: Bhaskar Roy, et autres
Publié: (2025)

Co‐Occurrence of Myasthenia Gravis and Facioscapulohumeral Muscular Dystrophy: A Case Series and Review of Literature
par: Giulia Tammam, et autres
Publié: (2026)

Rituximab in New‐Onset Generalized Myasthenia Gravis: Long‐Term Follow‐Up of the RINOMAX Clinical Trial
par: Jing Wu, et autres
Publié: (2025)

Unmasking Anti‐CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments
par: Vincent Fabry, et autres
Publié: (2025)

Robotic Thymectomy for Myasthenia Gravis: Analysis of the Surgical and Neurological Outcomes After a 20 Years' Experience
par: Giovanni M. Comacchio, et autres
Publié: (2025)

Correction to “Efgartigimod for Generalized Myasthenia Gravis: A Multicenter Real‐World Cohort Study in China”
Publié: (2025)

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis
par: Lei Jin, et autres
Publié: (2025)

Intracutaneous Amyloid Deposition is Associated With Nerve Conduction Studies Deterioration in Presumed Asymptomatic Pathogenic Variant TTR Carriers
par: Nina Schulz, et autres
Publié: (2025)

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
par: Nizar Chahin, et autres
Publié: (2025)

Intraepineurial Fat Fraction: A Novel MR Neurography‐Based Biomarker in Transthyretin Amyloidosis Polyneuropathy
par: Eva Sole Cruz, et autres
Publié: (2025)

Can Non‐Thymomatous Late‐Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta‐Analysis
par: Jiaxin Chen, et autres
Publié: (2025)

Robotic Extended Thymectomy in Late‐Onset Myasthenia Gravis: A 21‐Year Retrospective Cohort Study of 172 Patients
par: Luyu Huang, et autres
Publié: (2025)

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study
par: Dingxian He, et autres
Publié: (2026)

Risk of New‐Onset Myasthenia Gravis Following COVID ‐19 Infection and Vaccination: A Population‐Based Case–Control Study
par: Tasneem Kab, et autres
Publié: (2026)

Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study
par: Gregorio Spagni, et autres
Publié: (2025)

Bulbar muscle impairment in patients with late onset Pompe disease: Insight from the French Pompe registry
par: Emilie Retailleau, et autres
Publié: (2024)

Nonamyloidogenic TTR gene variants c.76G>A and c.337‐18G>C are not associated with idiopathic small‐fiber neuropathy
par: Céline Konecki, et autres
Publié: (2024)

Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO
par: Henry J. Kaminski, et autres
Publié: (2025)

Testing for Acetylcholine Receptor and Muscle‐Specific Tyrosine Kinase Antibodies by Fixed Cell‐Based Assay in Clinical Practice: Positive Predictive Value for Myasthenia Gravis
par: Cathy Meng Fei Li, et autres
Publié: (2025)

Factors affecting the topography of nitrous oxide‐induced neurological complications
par: Eva Sole Cruz, et autres
Publié: (2024)

Diagnostic Challenges of LRP4 Antibody Testing in Myasthenia Gravis: A Case Series of Four LRP4 Positive Cases With Uncertain Diagnostic Significance
par: Katherine Rosella Kinnard, et autres
Publié: (2026)

TTR Gene Screening Since the Advent of Biotherapies in France: A Nationwide Retrospective Survey Between 2018 and 2023
par: Abd El Kader Ait Tayeb, et autres
Publié: (2025)

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker
par: Tiancheng Luo, et autres
Publié: (2025)

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension
par: Tuan H. Vu, et autres
Publié: (2025)